ROME Therapeutics Raises $72 Million in Series B Funding for Cutting-Edge Cancer and Autoimmune Disease Therapies

ROME Therapeutics is thrilled to announce the successful closing of a funding round that has raised an impressive $72 million, a significant boost for the company as it pioneers a transformative approach to treating cancer and autoimmune diseases. Established in April 2020 and based in Cambridge, Massachusetts, ROME is uniquely positioned at the forefront of genetic research by leveraging the untapped potential of the repeatome—segments of DNA once dismissed as "junk." This innovative focus aligns with the company's mission to develop groundbreaking therapies that make a meaningful difference in patients' lives. With several drug targets identified and multiple discovery programs already underway, the recent influx of capital will enable ROME to accelerate its research efforts and expand its portfolio of discoveries. The company has brought together an extraordinary team of experts across oncology, immunology, virology, and machine learning, ensuring a multidisciplinary approach to its scientific inquiries. With the guidance of esteemed partners like GV, ARCH Venture Partners, and Partners Innovation Fund, ROME is well-equipped to navigate this uncharted territory in biology. The funding will be instrumental in driving ROME's vision forward, ultimately aiming to unlock new, effective treatment options for those battling challenging health conditions. As ROME Therapeutics continues to break new ground in genomic medicine, the implications of their work have the potential to reshape the future of therapeutic drugs and benefit countless patients worldwide. For more information on ROME Therapeutics and its pioneering initiatives, visit www.rometx.com.